Angioimmunoblastic T Cell Lymphoma Associated with Immune Checkpoint Inhibitor Treatment

Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive lymphoma that accounts for approximately 18% of natural killer/T-cell lymphomas.1 AITL typically affects older men and manifests at nodal and extranodal sites with B symptoms, lymphadenopathy, hematologic abnormalities, and, in up to 50% of cases, cutaneous manifestations.1, 2, 3 We report a case of AITL with a severe skin eruption developing during checkpoint inhibitor therapy.